CRDF
Price
$3.45
Change
+$0.05 (+1.47%)
Updated
Jan 17 closing price
Capitalization
229.51M
40 days until earnings call
RGNX
Price
$7.37
Change
+$0.22 (+3.08%)
Updated
Jan 17 closing price
Capitalization
365.15M
45 days until earnings call
Ad is loading...

CRDF vs RGNX

Header iconCRDF vs RGNX Comparison
Open Charts CRDF vs RGNXBanner chart's image
Cardiff Oncology
Price$3.45
Change+$0.05 (+1.47%)
Volume$1.28M
Capitalization229.51M
REGENXBIO
Price$7.37
Change+$0.22 (+3.08%)
Volume$681.03K
Capitalization365.15M
CRDF vs RGNX Comparison Chart
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. RGNX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Hold and RGNX is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CRDF: $3.45 vs. RGNX: $7.37)
Brand notoriety: CRDF and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 51% vs. RGNX: 45%
Market capitalization -- CRDF: $229.51M vs. RGNX: $365.15M
CRDF [@Biotechnology] is valued at $229.51M. RGNX’s [@Biotechnology] market capitalization is $365.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRDF and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • CRDF’s TA Score: 3 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than CRDF.

Price Growth

CRDF (@Biotechnology) experienced а -4.43% price change this week, while RGNX (@Biotechnology) price change was -1.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

CRDF is expected to report earnings on May 01, 2025.

RGNX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($365M) has a higher market cap than CRDF($230M). RGNX YTD gains are higher at: -4.657 vs. CRDF (-20.507). CRDF has higher annual earnings (EBITDA): -46M vs. RGNX (-217.82M). RGNX has more cash in the bank: 255M vs. CRDF (57.7M). CRDF has less debt than RGNX: CRDF (1.69M) vs RGNX (84.1M). RGNX has higher revenues than CRDF: RGNX (84.3M) vs CRDF (688K).
CRDFRGNXCRDF / RGNX
Capitalization230M365M63%
EBITDA-46M-217.82M21%
Gain YTD-20.507-4.657440%
P/E RatioN/AN/A-
Revenue688K84.3M1%
Total Cash57.7M255M23%
Total Debt1.69M84.1M2%
FUNDAMENTALS RATINGS
CRDF vs RGNX: Fundamental Ratings
CRDF
RGNX
OUTLOOK RATING
1..100
6422
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4192
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (68) in the null industry is in the same range as RGNX (75) in the Biotechnology industry. This means that CRDF’s stock grew similarly to RGNX’s over the last 12 months.

CRDF's Profit vs Risk Rating (86) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to RGNX’s over the last 12 months.

CRDF's SMR Rating (98) in the null industry is in the same range as RGNX (98) in the Biotechnology industry. This means that CRDF’s stock grew similarly to RGNX’s over the last 12 months.

CRDF's Price Growth Rating (41) in the null industry is somewhat better than the same rating for RGNX (92) in the Biotechnology industry. This means that CRDF’s stock grew somewhat faster than RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (26) in the Biotechnology industry is significantly better than the same rating for CRDF (100) in the null industry. This means that RGNX’s stock grew significantly faster than CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFRGNX
RSI
ODDS (%)
N/A
Bullish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
78%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
86%
MACD
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 5 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
80%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 5 days ago
85%
View a ticker or compare two or three
Ad is loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with AKBLF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then AKBLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
+1.47%
AKBLF - CRDF
37%
Loosely correlated
N/A
CMRX - CRDF
37%
Loosely correlated
-3.01%
ABSI - CRDF
33%
Loosely correlated
+3.57%
VRPX - CRDF
32%
Poorly correlated
-2.06%
RGNX - CRDF
32%
Poorly correlated
+3.08%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+3.08%
DNLI - RGNX
50%
Loosely correlated
+1.20%
BEAM - RGNX
49%
Loosely correlated
+0.17%
EDIT - RGNX
48%
Loosely correlated
-1.61%
RCKT - RGNX
47%
Loosely correlated
+0.98%
NTLA - RGNX
47%
Loosely correlated
+0.85%
More